Suppr超能文献

在国家癌症数据库中,骨肉瘤患者肿瘤坏死率达到 90%或更高与生存和健康的社会决定因素有关。

Ninety Percent or Greater Tumor Necrosis Is Associated With Survival and Social Determinants of Health in Patients With Osteosarcoma in the National Cancer Database.

机构信息

Department of Orthopaedic Surgery, Indiana University Health, Indiana University School of Medicine, Indianapolis, IN, USA.

出版信息

Clin Orthop Relat Res. 2023 Mar 1;481(3):512-522. doi: 10.1097/CORR.0000000000002380. Epub 2022 Sep 13.

Abstract

BACKGROUND

The histologic response of osteosarcoma to chemotherapy is commonly cited as a prognostic factor and typically graded as the percent necrosis of the tumor at the time of surgical resection. Few studies, to our knowledge, have examined the relationship of tumor necrosis relative to other factors. Existing studies are limited by prolonged enrollment periods or analysis of patient subsets without the strongest predictor of mortality: metastasis at diagnosis. Additionally, the definitive threshold value for a good histologic response is commonly set at more than 90% tumor necrosis with little evidence; some authors advocate other values.

QUESTION/PURPOSES: (1) Are there alternative cutoff values for a good response to chemotherapy in a large, national cohort of contemporarily treated patients with osteosarcoma? (2) How does the association of histologic response to survival in osteosarcoma compare with other clinicopathologic factors? (3) What patient and clinical factors are associated with the histologic response?

METHODS

We identified 2006 patients with osteosarcoma diagnosed between 2010 and 2015 in the National Cancer Database (NCDB), a registry that includes 70% of all new cancers diagnosed in the United States with 90% follow-up. Patients were excluded for missing documentation of percent tumor necrosis (21% [425 of 2006]) or if definitive resection was not performed (< 1% [1 of 2006]). A total of 1580 patients were included in the analysis, with a mean follow-up duration of 37 ± 22 months. A Kaplan-Meier survival analysis, stratified by the percent tumor necrosis after chemotherapy, was performed for the 5-year period. Other covariates examined were sex, race, socioeconomic score composite, insurance type, Charlson/Deyo score, distance from the hospital, and location (metropolitan, urban, or rural). Clinical and sociodemographic data including patient-identified race from the patient's medical record is input into the NCDB by certified registrars. The NCDB only allows coding of one primary race for each patient; thus, most of our patients were grouped as White or Black race and the remaining were grouped as Other for our analysis. A multiple Cox regression analysis was performed to evaluate the effect of percent necrosis compared with other demographic, clinicopathologic, and treatment effects on survival. Finally, a multiple logistic regression analysis was performed to assess demographic and clinicopathologic characteristics associated with percent necrosis.

RESULTS

Five-year overall survival for patients with histologic gradings of 90% to 94% necrosis (70% [95% confidence interval (CI) 60.6% to 79.7%) and 95% to 100% necrosis (74% [95% CI 68% to 80.3%) was not different between groups (p = 0.47). A comparison of histologic responses below 90% necrosis found no difference in survival between patients with decreasing histologic response (p > 0.05). Necrosis of less than 90% was associated with worse survival (HR 2.00 [95% CI 1.58 to 2.52]; p < 0.001 compared with more than 90% necrosis), and factors most associated with poor survival were metastasis (HR 2.85 [95% CI 2.27 to 3.59]; p < 0.001) and skip metastasis at the time of diagnosis (HR 2.52 [95% CI 1.64 to 3.88]; p < 0.001). On multivariate analysis, adjusting for demographic, clinicopathologic, and treatment factors, social determinants of health were negatively associated with percent necrosis of 90% or more, including uninsured status (OR 0.46 [95% CI 0.23 to 0.92]; p = 0.02 compared with private insurance) and lower socioeconomic status composite (OR for the lowest first and second quartiles were 0.63 [95% CI 0.44 to 0.90]; p = 0.01 and 0.70 [95% CI 0.50 to 0.96]; p = 0.03, respectively). Race other than White or Black (OR 0.61 [95% CI 0.40 to 0.94]; p = 0.02 compared with White race) was also negatively associated with percent necrosis of more than 90% after controlling for available covariates.

CONCLUSION

This study suggests that a cutoff of 90% necrosis provides the best prognostic value for patients with osteosarcoma undergoing chemotherapy. Other threshold values did not show different survival benefits. Sociodemographic factors were associated with histologic response less than 90%. These associations must be carefully understood not as cause and effect but likely demonstrating the effects of health disparities and access to care. Although we controlled for multiple variables in our analysis, broad variables such as race may have been associated with histologic response due to unaccounted confounders. Medical providers should be aware of these associations to ensure equitable access and delivery of care because access to care may be responsible for these associations. Future studies should examine potential drivers of this observation, such as a delay in presentation or deviation from standard of care practices.

LEVEL OF EVIDENCE

Level III, therapeutic study.

摘要

背景

骨肉瘤对化疗的组织学反应通常被认为是一个预后因素,通常按照肿瘤在手术切除时的坏死百分比进行分级。据我们所知,很少有研究检查肿瘤坏死与其他因素的关系。现有的研究受到研究纳入期延长或分析没有最强死亡率预测因子(诊断时转移)的患者亚组的限制。此外,良好组织学反应的明确阈值通常设定为超过 90%的肿瘤坏死,而证据很少;一些作者主张其他值。

问题/目的:(1)在接受骨肉瘤治疗的大型全国队列中,对于化疗反应良好的患者,是否存在其他替代截止值?(2)骨肉瘤中组织学反应与其他临床病理因素的生存相关性如何?(3)哪些患者和临床因素与组织学反应相关?

方法

我们在国家癌症数据库(NCDB)中确定了 2010 年至 2015 年间诊断为骨肉瘤的 2006 名患者,该数据库包含美国所有新诊断癌症的 70%,随访率为 90%。由于缺少肿瘤坏死百分比的记录(21%[2006 例中的 425 例])或未进行确定性切除术(<1%[2006 例中的 1 例]),排除了患者。对 1580 名患者进行了分析,平均随访时间为 37±22 个月。对化疗后 5 年内的肿瘤坏死百分比进行 Kaplan-Meier 生存分析。检查的其他协变量包括性别、种族、社会经济评分综合、保险类型、Charlson/Deyo 评分、与医院的距离和位置(城市、城市或农村)。包括患者病历中患者确定的种族在内的临床和社会人口统计学数据由认证登记员输入 NCDB。NCDB 仅允许为每位患者编码一种主要种族;因此,我们的大多数患者被归类为白人或黑人,其余的被归类为其他人进行分析。进行了多次 Cox 回归分析,以评估与其他人口统计学、临床病理和治疗效果相比,坏死百分比对生存的影响。最后,进行了多次逻辑回归分析,以评估与组织学反应相关的人口统计学和临床病理特征。

结果

组织学分级为 90%至 94%坏死(70%[95%置信区间(CI)为 60.6%至 79.7%)和 95%至 100%坏死(74%[95%CI 为 68%至 80.3%)的患者 5 年总生存率在组间无差异(p=0.47)。比较低于 90%坏死的组织学反应发现,随着组织学反应的降低,生存无差异(p>0.05)。小于 90%的坏死与较差的生存相关(HR 2.00[95%CI 为 1.58 至 2.52];p<0.001与大于 90%的坏死相比),与较差生存最相关的因素是转移(HR 2.85[95%CI 为 2.27 至 3.59];p<0.001)和诊断时的跳跃转移(HR 2.52[95%CI 为 1.64 至 3.88];p<0.001)。在多变量分析中,调整人口统计学、临床病理和治疗因素后,健康的社会决定因素与 90%或更高的肿瘤坏死百分比呈负相关,包括无保险状态(OR 0.46[95%CI 为 0.23 至 0.92];p=0.02 与私人保险相比)和社会经济状况综合评分较低(OR 第一和第二个四分位数的最低值分别为 0.63[95%CI 为 0.44 至 0.90];p=0.01 和 0.70[95%CI 为 0.50 至 0.96];p=0.03)。除白人或黑人以外的种族(OR 0.61[95%CI 为 0.40 至 0.94];p=0.02 与白种人相比)也与化疗后肿瘤坏死百分比大于 90%呈负相关,在控制了可用的协变量后。

结论

本研究表明,90%坏死的截止值为接受化疗的骨肉瘤患者提供了最佳的预后价值。其他阈值没有显示出不同的生存获益。社会人口统计学因素与低于 90%的组织学反应相关。这些关联必须仔细理解,而不是因果关系,因为它们可能表明健康差距和获得护理的机会。尽管我们在分析中控制了多个变量,但广泛的变量(如种族)可能由于未被记录的混杂因素而与组织学反应相关。医疗服务提供者应了解这些关联,以确保公平获得和提供护理,因为获得护理可能是这些关联的原因。未来的研究应该检查这种观察结果的潜在驱动因素,例如就诊时间延迟或偏离标准护理实践。

证据水平

III 级,治疗研究。

相似文献

引用本文的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验